Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph early_phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Not yet recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

not_yet_recruiting133%
recruiting133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1

Timed Aspirin Chronobiome Study

NCT03590821
unknownphase_2

Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma

NCT03896113
recruitingphase_4

NSAIDs vs. Coxibs in the Presence of Aspirin

NCT03699293

Clinical Trials (3)

Showing 3 of 3 trials
NCT03590821Early Phase 1

Timed Aspirin Chronobiome Study

Not Yet Recruiting
NCT03896113Phase 2

Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma

Unknown
NCT03699293Phase 4

NSAIDs vs. Coxibs in the Presence of Aspirin

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3